• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » FDA panel recommends reducing regulatory burden on cardiac devices

FDA panel recommends reducing regulatory burden on cardiac devices

September 12, 2013 By Ingrid Mezo

A panel of experts yesterday recommended the FDA down-classify several types of cardiac devices from the high-risk Class III category to the less-stringent Class II.

The panel evaluated external cardiac compressors, external pacemaker pulse generators and triple-chamber pacing system analyzers. External cardiac compressors and external pacemaker pulse generators are so-called "pre-amendment Class III devices," meaning they were grandfathered in when Congress passed the Medical Device Amendments in 1976, according to the FDA

If the FDA follows the panel’s recommendation, the devices would need to meet the same regulatory burden required of them so far under the watchdog agency’s 510(k) clearance program, a less burdensome path than the pre-market approval program required for Class III devices. But if the FDA keeps them as Class III devices, they may need to undergo new clinical trials.

Triple-chamber pacing systems are now classified as Class III, because they came onto the market after the amendments. The FDA proposes to down-classify them to Class II with special controls.

External cardiac compressors

There are 2 types of external cardiac compressors, or chest compressors, both are used to aid in cardiopulmonary resuscitation. Automated ECCs are powered manually, pneumatically or electrically and are placed directly on the patient’s chest to provide automatic chest compression at a fixed compression rate and depth, according to the FDA.

The 2nd type of ECCs are CPR aids, which provide audio and/or visual feedback to assist emergency personnel in maintaining the recommended rate and depth of compression during CPR. They go either beneath the hands of the medical professional or in the vicinity of the cardiac arrest victim, the agency noted.

The FDA’s Circulatory System Devices Panel generally agreed yesterday that both types of ECC are safe and effective.

"There is no question that when a person arrests, if you don’t do something, the person is dead. That’s zero survival," said Dr. Jeffrey Borer of State University of New York, Downstate Medical Center in New York.

"Now the optimal approach would be to start with manual compressions. If you can’t carry on because some situations preclude doing the ideal CPR technique, you had to have a way to continue the compressions somehow with a device like this, that’s probably better than nothing," Borer said. "And, if we look at the data that’s presented to us … there were positive outcomes, so I think we do have some evidence that this device can support survival."

A majority of panelists also agreed with the FDA’s proposal that general controls and software design controls are adequate for CPR devices without feedback. For CPR devices with feedback, they agreed with the agency’s proposal to use special controls including performance testing, labeling, human factors testing and analysis, electrical safety and electromagnetic compatibility testing where appropriate, and software verification validation and hazard analysis.

Both ECC types, according to the majority, should be down-classified to Class II, though a small minority argued that the devices should remain in the more stringent Class III until more clinical trial data can be gathered.

"There was a suggestion for potentially modifying the devices to have audible signals, and certainly post-market surveillance would be important," panel chairman Dr. Richard Page of the University of Wisconsin School of Medicine & Public Health said.

External pacemaker pulse generators, triple chamber pacing system analyzers

During a later, same-day session, the panel generally agreed with the FDA’s proposal to down-classify external pacemaker pulse generators and triple-chamber pacing system analyzers with external pacing capability to Class II with special controls, "with some word-smithing" even though these devices are life-supporting.

EPPGs have a power supply and electronic circuits that produce a periodic electrical pulse to stimulate the heart. They’re used outside the body as a temporary substitute for the heart’s intrinsic pacing system, until a permanent pacemaker can be implanted, or to control irregular heartbeats in patients following cardiac surgery or a myocardial infarction. They may be adjusted for impulse strength, duration, R-wave sensitivity, and other pacing variables, according to the FDA.

Triple-chamber pacing system analyzers with external pacing capability provide pacing and sensing in up to 3 heart chambers while pacemakers or defibrillators are implanted, so that the placement and integrity of the implants’ pacing leads can be determined, the agency said.

The panel’s recommendation came despite opposition in public commentary from Caitlin Kennedy, a senior fellow at the National Research Center for Women & Families.

Kennedy urged the panel not to recommend down-classification of EPPGs and PSAs because certain types of device failures can cause cardiac arrhythmias and death.

"It undermines public health and the integrity of the FDA when life-sustaining devices that have resulted in death are classified as Class II, moderate-risk devices. They are high-risk, not moderate-risk," she said.

Kennedy listed 4 important safeguards that keeping devices in Class III provides: Proof of safety and efficacy based on short-term clinical trials; the FDA’s authority to require long-term post-market surveillance as a condition of approval; the FDA’s authority to inspect manufacturing facilities prior to approval; and the agency’s authority to rescind approval if the device is later found to be unsafe.

"We hear you about issues of safety," Page said at the end of the day. "I think I speak for this committee in acknowledging that these are life-supporting devices, but I’m hearing a strong consensus from this panel that we will be able to provide adequate assurance of safety and efficacy and proper level of rigor, in terms of labeling and classification, in the actions that we’ve undertaken today, so we feel that the regulation is appropriate for the devices that we’ve discussed today."

Filed Under: Food & Drug Administration (FDA), News Well, Regulatory/Compliance, Resuscitation Tagged With: Cardiac Rhythm Management

In case you missed it

  • HistoSonics, GE Healthcare agree to integrate ultrasound into sonic beam liver therapy
  • Pfizer, BioNTech moving forward on seeking COVID-19 vaccine EUA for youngest children
  • Zimmer Biomet narrowly avoids shareholder rebuke on executive pay
  • FDA says Philips ventilator recall produced over 21,000 device reports, 124 deaths
  • Boston Scientific’s Acurate Neo2 valve performs well in studies
  • MicroTransponder reports first commercial implantation of its stroke rehab neurostim system
  • Ambu replaces CEO with new leadership
  • Moderna’s first bivalent COVID-19 vaccine booster candidate shows promise
  • AdvaMed joins Biden’s Joint Supply Chain Resilience Working Group
  • FDA clears Accelus’ Toro-L interbody fusion system
  • Teleflex’s UroLift cleared in China to treat BPH
  • Globus Medical announces first surgeries with Excelsius3D
  • Abbott reports positive data on heart valve therapies
  • OncoRes Medical raises another $12.5M
  • NeuroMetrix’s Quell neuromodulation device wins FDA de novo nod to treat fibromyalgia
  • Inogen appoints Agnes Lee as senior VP of investor relations, strategic planning
  • Google Health hires FDA’s chief digital health officer

RSS From Medical Design & Outsourcing

  • Zimmer Biomet narrowly avoids shareholder rebuke on executive pay
    An unusually large share of Zimmer Biomet (NYSE:ZBH) investors voted against the orthopedics company’s pay packages for top executives at the annual shareholder meeting. About 54% of voting shareholders supported the pay packages of the company’s five top-paid executives at the May 13 meeting, according to results filed with the SEC yesterday. In 2021, nearly 93%… […]
  • BD, Mitsubishi Gas Chemical partner on better materials for plastic syringes
    BD (NYSE:BDX) announced that it partnered with Mitsubishi Gas Chemical Company on applying new technology to pre-fillable syringes. MGC develops the Oxycapt technology designed to integrate the best of plastic and glass for plastic syringes. BD and Tokyo-based MGC will work together to apply Oxycapt technology to the next generation of pre-fillable syringes (PFS) for advanced… […]
  • Ambu replaces CEO with new leadership
    Ambu today said it has hired board member Britt Meelby Jensen to replace CEO Juan Jose Gonzalez, effective tomorrow. “Since Juan Jose Gonzalez joined as CEO in 2019, Ambu has made good progress and achieved important milestones on the strategic transformation into the world’s largest single-use endoscopy company,” Ambu Chair Jørgen Jensen said in a… […]
  • AdvaMed joins Biden’s Joint Supply Chain Resilience Working Group
    AdvaMed executive Abby Pratt has joined the executive committee for the Biden administration’s Joint Supply Chain Resilience Working Group, the medtech industry association said today. The working group’s members from government and industry will assist with implementation of the National Strategy for a Resilient Public Health Supply Chain. Pratt oversees supply chain issues as SVP… […]
  • Toray develops new stretchable film for medical devices
    Toray Industries has a new stretchable film based on its proprietary polymer Reactis technology, with potential applications that include robotics and biological and industrial sensors. Tokyo-based Toray said it shipped samples to customers and plans research and development efforts to commercialize the new grade of film. “Recent years have increased the potential for developing stretchable… […]
  • Google Health hires FDA’s chief digital health officer
    Former FDA Chief Digital Health Officer of Global Strategy and Innovation Bakul Patel has started a new job with Google after 13 years with the regulatory agency. Patel became senior director, global digital health strategy and regulatory for Google Health earlier this month, he said on LinkedIn. Patel recounted highlights of his “incredible journey since… […]
  • Expect more heart and lung failure years after COVID, Abbott’s heart failure CMO says
    Two years into the COVID-19 pandemic, we know more than ever about the SARS-CoV-2 virus and how quickly it moves to ravage the human body. What remains to be seen is how the virus — and perhaps more importantly, our immune system’s response to it — will affect the health of people long after infection,… […]
  • FDA moves forward with Voluntary Improvement Program to bolster medical device quality
    Kathryn Burke, Emergo Group The U.S. Food and Drug Administration has issued new draft guidance to establish a full-blown voluntary program for improving quality-related processes in medical device manufacturing following promising results of a pilot program. The FDA guidance stems from a pilot undertaken by the agency along with the Medical Device Innovation Consortium (MDIC) in 2018.… […]
  • How Minnetronix Medical helped Lazurite with its wireless surgical camera
    Minnetronix Medical (St. Paul, Minnesota) has played an important development and manufacturing partner role with Lazurite’s wireless surgical camera system. It’s been nearly two months since Lazurite (formerly Indago) announced FDA 510(k) clearance of its ArthroFree system. ArthroFree combines proprietary low-heat, high-intensity Meridiem light engine technology with advanced camera, battery and wireless transmission technologies and… […]
  • Instron releases TrendTracker data analysis workflow platform
    Instron announced that it released the TrendTracker module in Bluehill Central for accelerating data analysis workflows. Norwood, Massachusetts-based Instron designed TrendTracker with an intuitive interface to improve the data analysis workflow of single or multi-location materials testing laboratories. According to a news release, the platform features quick searching and the ability to display and analyze… […]
  • Henry Schein hires former Medline veteran to drive ‘One Distribution’ push
    Henry Schein (Nasdaq:HSIC) today named Dirk Benson as VP and chief commercial officer of the medical device manufacturer and distributor’s North America Distribution Group (NADG). Melville, New York-based Henry Schein is the world’s largest provider of health care supplies and services for office-based dental and medical practitioners, and NADG is the company’s largest business group. The… […]

Primary Sidebar

DeviceTalks Weekly

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS